Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

23 Sep 2010

St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc., a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

23 Sep 2010

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

W. L. Gore & Associates announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.

23 Sep 2010

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.

23 Sep 2010

CSI to present CALCIUM 360° Study results at TCT symposium

Cardiovascular Systems, Inc., announced today that its CALCIUM 360° Study, the first-of-its kind prospective, randomized feasibility study, demonstrated the safety and effectiveness of plaque modification with the Diamondback 360 PAD System versus the standard of care treatment (balloon angioplasty) in below-the-knee arteries.

23 Sep 2010

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.

23 Sep 2010

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberte Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.

23 Sep 2010

Study finds certain MRI sequences as accurate methods of assessing stent stenosis

Researchers have found that magnetic resonance imaging (MRI) may be sufficient for the routine surveillance of some great vessel (primary blood vessels [e.g., aorta and vena cavae]) stents that are commonly used to treat congenital heart defects (a defect in the structure of the heart and great vessels that is present at birth) in children and young adults, according to a study in the October issue of the American Journal of Roentgenology (www.ajronline.org). MRI is a noninvasive medical test that helps physicians diagnose and treat medical conditions.

22 Sep 2010

Study: Stricture recurrence rate is low, recurrence can be retreated endoscopically

Researchers from Italy have reported results from more than 10 years of follow-up showing that the placement of multiple endoscopic stents for the treatment of postoperative biliary strictures remains excellent with a low rate of stricture recurrence after this lengthy period of time. When strictures do recur, they can be safely and successfully retreated endoscopically. The study appears in the September issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).

22 Sep 2010

ART closes new $8.5 million venture financing round

Arterial Remodeling Technologies ("ART") announced today that it has closed on a new venture financing round of $8.5 million from existing investors Matignon Technologies and Amundi Private Equity Funds, along with new investor InnoBio Fund managed by CDC Entreprises. Total investment in the Company is now $17 million.

22 Sep 2010

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

The first in-human study of a robotically assisted percutaneous coronary intervention system demonstrated that the technique was safe and feasible. The results of the study were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

22 Sep 2010

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Boston Scientific Corporation today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent. The results provided 30-day and nine-month clinical outcomes and nine-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the PROMUS Element Stent.

22 Sep 2010

Biodegradable polymers represent future of stent design

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

21 Sep 2010

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.

21 Sep 2010

New interventional technique effective for controlling hepatic arterial hemorrhage after PD

Delayed hepatic arterial hemorrhage after pancreaticoduodenectomy (PD) is not a common but a fatal complication, occurring in 7% of all patients. Its ideal management remains unclear and controversial. A research article published on August 7, 2010 in the World Journal of Gastroenterology addresses this question. The authors reported the clinical outcome of 9 patients with life-threatening hemorrhage from a ruptured hepatic artery pseudoaneurysm after PD after treatment with a new interventional technique, namely placement of stent-grafts.

21 Sep 2010

FDA approves Medtronic's Integrity Coronary Stent System

Delivering another innovation for interventional cardiology, Medtronic, Inc.,announced today the U.S. Food and Drug Administration (FDA) approval of the Integrity Coronary Stent System. The new platform for Medtronic's coronary stents, including the Integrity bare-metal stent, is based on an advance in biomedical engineering called continuous sinusoid technology that enables the exploration of other breakthrough device concepts such as a polymer free drug filled stent.

21 Sep 2010

Corindus announces clinical results of CorPath 200 System

Corindus Vascular Robotics announced the results of the first clinical study of the CorPath 200 System and invites attendees of the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference (September 21-25 in Washington, DC) to experience firsthand the CorPath 200 System.

21 Sep 2010

$Neovasc commences enrollment in Reducer trial for refractory angina$

Neovasc commences enrollment in Reducer trial for refractory angina

Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.

20 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

CID to provide update on Cre8 polymer-free DES program at TCT 2010

CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".

17 Sep 2010

Stent News and Research

Further Reading

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

St. Jude Medical to highlight OCT product platform at TCT meeting

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

CSI to present CALCIUM 360° Study results at TCT symposium

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Study finds certain MRI sequences as accurate methods of assessing stent stenosis

Study: Stricture recurrence rate is low, recurrence can be retreated endoscopically

ART closes new $8.5 million venture financing round

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Biodegradable polymers represent future of stent design

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

New interventional technique effective for controlling hepatic arterial hemorrhage after PD

FDA approves Medtronic's Integrity Coronary Stent System

Corindus announces clinical results of CorPath 200 System

Neovasc commences enrollment in Reducer trial for refractory angina

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

CID to provide update on Cre8 polymer-free DES program at TCT 2010

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News